10.1002/chem.201700440
Chemistry - A European Journal
COMMUNICATION
Photophysical properties of 6 were also assessed, in order to
investigate the effect of replacing a chloro for a fluoro substituent
in the 2- position of phenanthroline, given our initial research
incentives to develop PET-optical probes. We therefore verified
that these Re(I) complexes afforded similar quantum yields (Φ =
0.3%), lifetimes (τ = 27 - 41 ns), emission maxima (λex = 410
nm, λem = 653 - 654 nm) and monoexponential decay profiles in
DMSO (SI 4.1 - 4.3).
In summary, the fluorine-18 radiolabelling of a ligand complexed
to Re(I) was found to afford optimal RCYs under remarkably
mild conditions, without the need for azeotropic distillation and
with a reduction of >100°C for the optimal temperature. Further
investigations will clarify the involvement of the Re(I) centre in
the radiofluorination mechanism, and will seek to apply this
radiolabelling strategy toward improving the RCY of existing
PET tracers, as well as toward accessing new PET and PET-
optical probes.
Keywords: fluorine-18 radiolabelling • microfluidics • PET
chemistry • rhenium complexes • late stage fluorination
[1]
Representative examples: a) G. Pascali, P. Watts and P. A. Salvadori,
Nucl. Med. Biol. 2013, 40, 776–787; b) A. Lebedev, R. Miraghaie, K.
Kotta, C. E. Ball, J. Zhang, M. S. Buchsbaum, H. C. Kolb and A.
Elizarov, Lab Chip 2013, 13, 136–145; c) C.-C. Lee, G. Sui, A. Elizarov,
C. J. Shu, Y.-S. Shin, A. N. Dooley, J. Huang, A. Daridon, P. Wyatt, D.
Stout, H. C. Kolb, O. N. Witte, N. Satyamurthy, J. R. Heath, M. E.
Phelps, S. R. Quake and H.-R. Tseng, Science 2005, 310, 1793–1796;
d) C. J. Steel, A. T. O’Brien, S. K. Luthra and F. Brady, J. Label. Compd.
Radiopharm. 2007, 50, 308–311; e) P. W. Miller, H. Audrain, D. Bender,
A. J. deMello, A. D. Gee, N. J. Long and R. Vilar, Chem. Eur. J. 2011,
17, 460–463.
[2]
[3]
S. M. Ametamey, M. Honer and P. A. Schubiger, Chem. Rev. 2008, 108,
1501–1516.
Representative examples: a) C. F. Lemaire, J. J. Aerts, S. Voccia, L. C.
Libert, F. Mercier, D. Goblet, A. R. Plenevaux and A. J. Luxen, Angew.
Chem. Int. Ed. 2010, 49, 3161–3164; b) R. Richarz, P. Krapf, F. Zarrad,
E. A. Urusova, B. Neumaier and B. D. Zlatopolskiy, Org. Biomol. Chem.
2014, 12, 8094-8099; c) J. Aerts, S. Voccia, C. Lemaire, F. Giacomelli,
D. Goblet, D. Thonon, A. Plenevaux, G. Warnock and A. Luxen.
Tetrahedron Lett. 2010. 51, 64-66; d) S.H. Wessmann, G. Henriksen
and H. J. Wester. NuklearMedizin. 2012. 51, 1-31; e) F. Basuli, X.
Zhang, E. M. Jagoda, P. L. Choyke and R. E. Swenson. Nucl. Med. Biol.
2016. 43, 770-772; f) J-H. Chun, S. Telu, S. Lu and V. W. Pike. Org.
Biomol. Chem. 2013. 11, 5094-5099.
Experimental Section
Aqueous
[
18F]fluoride was produced on an IBA Cyclone 18 Twin
cyclotron (ANSTO, Camperdown, Australia) using the 18O(p,n)18F nuclear
reaction. Microfluidic radiosyntheses were performed in Discovery Mode
using a NanoTek LF Microfluidic Synthesis System (Advion, Ithaca, NY)
connected to a standard laptop using the NanoTek software, V1.4.0 GMP
Lite. Microreactors were made of fused silica tubing (100 µm × 2 m),
coiled tightly into a brass ring containing a thermoresistent polymer to
hold the tubing in place. RadioHPLC analyses were carried out using a
Shimadzu system comprised of a CBM-20 controller, LC-20AD pump,
SIL-20AHT autoinjector, SPD-M20A PDA detector (for UV analyses) and
a Lablogic Posi-RAM gamma detector. Analyses were performed using
isocratic conditions consisting of CH3CN/H2O/TFA mobile phases
(7.95:91.95:0.10% v/v for [18F]4 and 64.95:34.95:0.10% v/v for [18F]6), on
a Chromolith RP column (monolith system, Merck, 50 × 4.6 mm). RCYs
were calculated using the radio-HPLC profiles, integrating the
radioproduct peak against all the other radioactive peaks (inclusive of the
unreacted [18F]fluoride), using Laura V4.1.70 SP2 HPLC data analysis
software.
[4]
[5]
[6]
L. Matesic, A. Kallinen, N. Wyatt, T. Q. Pham, I. Greguric and G.
Pascali, Aust. J. Chem. 2014, 68, 69–71.
S. Lindner, C. Rensch, S. Neubaur, M. Neumeier, R. Salvamoser, V.
Samper and P. Bartenstein, Chem. Commun. 2016, 52, 729–732.
Representative examples: a) Z. Li, T. P. Lin, S. Liu, C. W. Huang, T. W.
Hudnall, F. P. Gabbai and P. S. Conti, Chem. Commun. 2011, 47,
9324–9326; b) S. Liu, D. Li, Z. Zhang, S. G. K. Prakash, P. S. Conti and
Z. Li, Chem. Commun. 2014, 50, 7371–7373; c) T. Temma, N. Kondo,
M. Ono and H. Saji, J. Nucl. Med. 2015, 56, 1127; d) J. A. Hendricks, E.
J. Keliher, D. Wan, S. A. Hilderbrand, R. Weissleder and R. Mazitschek,
Angew. Chem. 2012, 51, 4603–4606; e) K. Chen, Z.-B. Li, H. Wang, W.
Cai and X. Chen, Eur. J. Nucl. Med. Mol. Imaging, 2008, 35, 2235–
2244; f) F. Ducongé, T. Pons, C. Pestourie, L. Hérin, B. Thézé, K.
Gombert, B. Mahler, F. Hinnen, B. Kühnast, F. Dollé, B. Dubertret and
B. Tavitian, Bioconjugate Chem. 2008, 19, 1921–1926; g) W. Guo, X.
Sun, O. Jacobson, X. Yan, K. Min, A. Srivatsan, G. Niu, D. O.
Kiesewetter, J. Chang and X. Chen, ACS Nano 2015, 9, 488–495.
Representative examples: a) M. V. Werrett, P. J. Wright, P. V. Simpson,
P. Raiteri, B. W. Skelton, S. Stagni, A. G. Buckley, P. J. Rigby and M.
Massi, Dalton. Trans. 2015, 44, 20636–20647; b) C. A. Bader, R. D.
Brooks, Y. S. Ng, A. Sorvina, M. V. Werrett, P. J. Wright, A. G. Anwer,
D. A. Brooks, S. Stagni, S. Muzzioli, M. Silberstein, B. W. Skelton, E. M.
Goldys, S. E. Plush, T. Shandala and M. Massi, RSC Adv. 2014, 4,
16345–16351.
The microfluidic experiments were carried out on the scale of 29±10 MBq,
and afforded [18F]6 with a molar activity of 71±12 MBq.nmol-1.
[7]
Experimental details concerning the general syntheses, structure
elucidation, radiochemistry and photophysical characterisations of the
reported compounds can be found within the SI sections 5.1 – 5.3.
Acknowledgements
[8]
[9]
G. Pascali, L. Matesic, T. L. Collier, N. Wyatt, B. H. Fraser, T. Q. Pham,
P. A. Salvadori and I. Greguric, Nat. Protoc., 2014, 9, 2017–29.
Representative examples: a) G. Pascali, M. De Simone, L. Matesic, I.
Greguric and P. A. Salvadori, J. Flow Chem. 2014, 4, 86–91; b) T. R.
Neal, S. Apana and M. S. Berridge, J. Label. Compd. Radiopharm.,
2005, 48, 557–568.
This work has been partially funded by the Australian Institute
for Nuclear Science and Engineering (AINSE) via the provision
of a Postgraduate Research Award (PGRA), and the Australian
Research Council (ARC) – Linkage grant LP1590101307. We
also acknowledge Nikolas Paneras for the cyclotron production,
as well as Dr. Lidia Matesic and Iveta Kurlapski for laboratory
support.
[10] G. Pascali, G. Nannavecchia, S. Pitzianti and P. A. Salvadori, Nucl.
Med. Biol. 2011, 38, 637 – 644.
This article is protected by copyright. All rights reserved.